Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016.. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MmPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJFMvPj[nLUC1JO69VQ>? MoPtV2FPT0WU
CAL-51 cell NFryNoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoT4TY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPiCwTR?= M2\YN3NCVkeHUh?=
ABC-1 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnnFTY5pcWKrdHnvckBw\iCqdX3hckBCSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y2KG6P NVzRd3hnW0GQR1XS
A2780 cell M3zmRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWLJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PVQhdk1? NETmb29USU6JRWK=
ES1 cell NVLMdpFDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwN{S5JI5O M{TmXHNCVkeHUh?=
HUTU-80 cell M2j1Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1e2emlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzlzIH7N MoTRV2FPT0WU
NCI-H292 cell Mkf6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIHTNpdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0> MUjTRW5ITVJ?
NB69 cell M3fqeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXnFWVNRUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?= M1HvVnNCVkeHUh?=
ES8 cell M1nNU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PnVGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNkBvVQ>? MkHEV2FPT0WU
BCPAP cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3LSVBYUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= MkDYV2FPT0WU
T-24 cell MnnTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{TRNGlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUhdk1? MnrkV2FPT0WU
EW-16 cell NHXabnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFXlRZBKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OSCwTR?= MVLTRW5ITVJ?
OVCAR-5 cell Mn7CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF3SeXlKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh|IH7N M1fTSnNCVkeHUh?=
SF126 cell NGK5R|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVvJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65OUBvVQ>? MofEV2FPT0WU
KP-4 cell M{DjVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYXJcohq[mm2aX;uJI9nKGi3bXHuJGtRNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkG3JI5O MUfTRW5ITVJ?
GAMG cell NWLh[GE2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3znWmlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOVEhdk1? M1HqdnNCVkeHUh?=
HOS cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXn4d5d[UW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU{KG6P MojaV2FPT0WU
CHL-1 cell M4D4S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkDHTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFEhdk1? NH3FOVJUSU6JRWK=
AGS cell NIjLVWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXPNSlZDUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P NFLXe4hUSU6JRWK=
MDA-MB-157 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1rUZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUKgcm0> MWPTRW5ITVJ?
HSC-3 cell NV;kb3A{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wNkBvVQ>? M362PXNCVkeHUh?=
CAL-72 cell MlKwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHHMWpVKdmirYnn0bY9vKG:oIHj1cYFvKEODTD23NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODJibl2= NUXmfIRbW0GQR1XS
NBsusSR cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1P0b2lvcGmkaYTpc44hd2ZiaIXtZY4hVkK|dYPTVkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOTNibl2= Ml\PV2FPT0WU
ES7 cell MnHZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFnHN4hKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVkhdk1? MmjUV2FPT0WU
H-EMC-SS cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\yTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2= M4XqS3NCVkeHUh?=
NCI-H1703 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWL4b|NGUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4ODNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4JI5O NXXhNWVPW0GQR1XS
BHT-101 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{j6ZmlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzJibl2= MXLTRW5ITVJ?
SK-OV-3 cell NVrBPIZrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTlbHNKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd3IH7N M2nwcXNCVkeHUh?=
EW-24 cell M3vxVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYfIUlFxUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDNibl2= MoG5V2FPT0WU
PSN1 cell NVP2U41QT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4CzeWlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFQhdk1? M{\V[3NCVkeHUh?=
OVCAR-8 cell MlfiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XEXmlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2= NGHmeGlUSU6JRWK=
NCI-H1563 cell NELEcG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2LM[mlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> MVvTRW5ITVJ?
SW756 cell NYHRd2h2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEnZPFRKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOyCwTR?= NVTXUWdRW0GQR1XS
A375 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG0JI5O MoDsV2FPT0WU
Ca9-22 cell MojSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmnKTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlI2KG6P NXLOeVBuW0GQR1XS
SW1990 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXzje4oxUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G5PVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjN{IH7N MXvTRW5ITVJ?
ES4 cell M1zTO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mle1TY5pcWKrdHnvckBw\iCqdX3hckBGWzRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkO5JI5O MljsV2FPT0WU
HCE-T cell NW\KSZV7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60OUBvVQ>? MnvFV2FPT0WU
MOLT-16 cell NWXVV2toT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPpeFRKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV|IH7N NHroV2pUSU6JRWK=
HSC-4 cell MoDqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoX5TY5pcWKrdHnvckBw\iCqdX3hckBJW0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPEBvVQ>? MlmxV2FPT0WU
NCI-SNU-1 cell MlvUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQDZibl2= MofDV2FPT0WU
EW-11 cell M4ixSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHK2blBKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46KG6P MoS1V2FPT0WU
HT-1080 cell M4jhdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHLaSI5KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7IH7N Mkn2V2FPT0WU
MES-SA/Dx5 cells Mm\ER5l1d3SxeHnjbZR6KGG|c3H5 M3nZdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GWy2VQT;EfFUh[2WubIOsJGlEPTB;NTDuUS=> NH\keHkzOzl|N{m4NS=>
SW1710 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnZU4pKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2= M170[HNCVkeHUh?=
EW-1 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYX5UldrUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zPCCwTR?= NVzONVF4W0GQR1XS
BV-173 cell NH\E[49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml;FTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P M3PDNXNCVkeHUh?=
TE-8 cell MoTFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3vNdmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFEhdk1? M{HTZXNCVkeHUh?=
G-401 cell M4\LeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60N{BvVQ>? M3\BRXNCVkeHUh?=
KOSC-2 cell NGH3NGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlGzTY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ2KG6P MnjzV2FPT0WU
HuCCT1 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVIhdk1? MYXTRW5ITVJ?
FADU cell MkL5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEmxS|ZKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P M3HNbnNCVkeHUh?=
MHH-ES-1 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHfSPVJKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54OTDuUS=> MmLJV2FPT0WU
ES3 cell MlPuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlLpTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5JI5O MWTTRW5ITVJ?
OVCAR-4 cell M{Doe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg4KG6P M125TnNCVkeHUh?=
HD-MY-Z cell M3:3dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhFNU2\LWqgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlkyKG6P MmTaV2FPT0WU
human JAR cell MkPwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFzEVoVKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? Ml\KV2FPT0WU
A427 cell NGPuVIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV;uNlBFUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xPyCwTR?= Mmj3V2FPT0WU
697 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWjJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwMUOgcm0> NYTifYVTW0GQR1XS
OVCAR-3 cell Mn72S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUjN[IY4UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N MXnTRW5ITVJ?
human NB14 cell NVHSdFllT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlzVTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj62OEBvVQ>? M1\ZNnNCVkeHUh?=
GB-1 cell MoPNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2jhVmlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uO|Ehdk1? NIXiZ2RUSU6JRWK=
COR-L105 cell NUK4ZW1KT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVr1ZnpMUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwN{[gcm0> MYTTRW5ITVJ?
647-V cell NXG1c2tIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkK4TY5pcWKrdHnvckBw\iCqdX3hckA3PDdvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uPUBvVQ>? MUnTRW5ITVJ?
human K5 cell NXz0clJOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2rwVmlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15IH7N NVf3fWRDW0GQR1XS
DMS-273 cell M1nPN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHfkTXZKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2yO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjB4IH7N Mof4V2FPT0WU
UM-UC-3 cell NHvHUYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVXIS5hKUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yNjDuUS=> M1P2ZXNCVkeHUh?=
HEL cell NGjwZmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWjJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> NV7lcmhpW0GQR1XS
human KU-19-19 cell M4DHW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnjaTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODlibl2= NXXsZVhrW0GQR1XS
MC-IXC cell M17pc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1fJO2lvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?= M4rQUHNCVkeHUh?=
human H4 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXzqfI5rUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNlUhdk1? NVq4Wow3W0GQR1XS
NUGC-3 cell M1r1Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUfKbItCUW6qaXLpeIlwdiCxZjDoeY1idiCQVVfDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN|IH7N M4TOfXNCVkeHUh?=
CHP-212 cell NHjXXJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWThOHZ1UW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5|NDDuUS=> NH65[oxUSU6JRWK=
human SW982 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEfD[ZdKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= MWPTRW5ITVJ?
C-33-A cell NFi4[49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGMuOzNvQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVghdk1? M1f5WHNCVkeHUh?=
PC-3 cell M2fWTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lki5JI5O NFn0V|BUSU6JRWK=
COLO-684 cell M4fpc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2K5RWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjJzIH7N NVj5TFJpW0GQR1XS
SNU-387 cell NVG5[|UzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS1|OEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlQ6KG6P MWnTRW5ITVJ?
U251 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2JI5O NWq0RVd5W0GQR1XS
A673 cell M3TMOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIT2eVNKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P NID2XZZUSU6JRWK=
human T47D cell MmnJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlT4TY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MU[uO|khdk1? NYr2NnNDW0GQR1XS
A549 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1L1NmlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlYhdk1? MYnTRW5ITVJ?
PC-14 cell MmPyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHzUe2NKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlQvPzNibl2= NVPmcpc6W0GQR1XS
A704 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>? NVjRWIhSW0GQR1XS
MCF7 cell MkD0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3exV2lvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOxMlM3KG6P MojhV2FPT0WU
PC3 cells MkXvSpVv[3Srb36gZZN{[Xl? MnjETY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF|IN88US=> NYCyTpZDOjF|NEG2O|U>
F-36P cells MlnCVJJwdGmoZYLheIlwdiCjc4PhfS=> M33aUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1? Ml[3NlE{PDF4N{W=
OCI-AML2 cells NFHUdXdRem:uaX\ldoF1cW:wIHHzd4F6 MoS0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCRQ1mtRW1NOiClZXzsd{whUUN3ME2wMlM2KM7:TR?= MXmyNVM1OTZ5NR?=
K562 cells M1jtOXBzd2yrZnXyZZRqd25iYYPzZZk> NYrRVW9mSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? NYrafJM3OjF|NEG2O|U>

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Unknown status Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00808418 Completed Prostate Cancer Synta Pharmaceuticals Corp. November 2008 Phase 1
NCT00522834 Terminated Melanoma Synta Pharmaceuticals Corp. August 2007 Phase 3
NCT00087997 Completed Soft Tissue Sarcoma Synta Pharmaceuticals Corp. July 2004 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID